Advances in cancer research最新文献_第2页

Small extracellular vesicles: Roles and clinical application in prostate cancer. 细胞外小泡：前列腺癌的作用和临床应用。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-12 DOI: 10.1016/bs.acr.2024.05.008

Caleb Smack, Benjamin Johnson, Julius O Nyalwidhe, O John Semmes, Lifang Yang

{"title":"Small extracellular vesicles: Roles and clinical application in prostate cancer.","authors":"Caleb Smack, Benjamin Johnson, Julius O Nyalwidhe, O John Semmes, Lifang Yang","doi":"10.1016/bs.acr.2024.05.008","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.05.008","url":null,"abstract":"Prostate cancer is a significant health problem in the United States. It is remarkably heterogenous, ranging from slow growing disease amenable to active surveillance to highly aggressive forms requiring active treatments. Therefore, being able to precisely determine the nature of disease and appropriately match patients to available and/or novel therapeutics is crucial to improve patients' overall outcome and quality of life. Recently small extracellular vesicles (sEVs), a subset of nanoscale membranous vesicles secreted by various cells, have emerged as important analytes for liquid biopsy and promising vehicles for drug delivery. sEVs contain various biomolecules such as genetic material, proteins, and lipids that recapitulate the characteristics and state of their donor cells. The application of existing and newly developed technologies has resulted in an increased depth of knowledge about biophysical structures, biogenesis, and functions of sEVs. In prostate cancer patients, tumor-derived sEVs can be isolated from biofluids, commonly urine and blood. They mediate intercellular signaling within the tumor microenvironment and distal organ-specific sites, supporting cancer initiation, progression, and metastasis. A mounting body of evidence suggests that sEV components can be potent biomarkers for prostate cancer diagnosis, prognosis, and prediction of disease progression and treatment response. Due to enhanced circulation stability and bio-barrier permeability, sEVs can be also used as effective drug delivery carriers to improve the efficacy and specificity of anti-tumor therapies. This review discusses recent studies on sEVs in prostate cancer and is focused on their role as biomarkers and drug delivery vehicles in the clinical management of prostate cancer.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"119-190"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling the complexity: Advanced methods in analyzing DNA, RNA, and protein interactions. 揭示复杂性：分析 DNA、RNA 和蛋白质相互作用的先进方法。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.acr.2024.06.010

Maria Leonor Peixoto, Esha Madan

{"title":"Unraveling the complexity: Advanced methods in analyzing DNA, RNA, and protein interactions.","authors":"Maria Leonor Peixoto, Esha Madan","doi":"10.1016/bs.acr.2024.06.010","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.06.010","url":null,"abstract":"Exploring the intricate interplay within and between nucleic acids, as well as their interactions with proteins, holds pivotal significance in unraveling the molecular complexities steering cancer initiation and progression. To investigate these interactions, a diverse array of highly specific and sensitive molecular techniques has been developed. The selection of a particular technique depends on the specific nature of the interactions. Typically, researchers employ an amalgamation of these different techniques to obtain a comprehensive and holistic understanding of inter- and intramolecular interactions involving DNA-DNA, RNA-RNA, DNA-RNA, or protein-DNA/RNA. Examining nucleic acid conformation reveals alternative secondary structures beyond conventional ones that have implications for cancer pathways. Mutational hotspots in cancer often lie within sequences prone to adopting these alternative structures, highlighting the importance of investigating intra-genomic and intra-transcriptomic interactions, especially in the context of mutations, to deepen our understanding of oncology. Beyond these intramolecular interactions, the interplay between DNA and RNA leads to formations like DNA:RNA hybrids (known as R-loops) or even DNA:DNA:RNA triplex structures, both influencing biological processes that ultimately impact cancer. Protein-nucleic acid interactions are intrinsic cellular phenomena crucial in both normal and pathological conditions. In particular, genetic mutations or single amino acid variations can alter a protein's structure, function, and binding affinity, thus influencing cancer progression. It is thus, imperative to understand the differences between wild-type (WT) and mutated (MT) genes, transcripts, and proteins. The review aims to summarize the frequently employed methods and techniques for investigating interactions involving nucleic acids and proteins, highlighting recent advancements and diverse adaptations of each technique.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"251-302"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modular formation of in vitro tumor models for oncological research/therapeutic drug screening. 用于肿瘤研究/治疗药物筛选的体外肿瘤模型的模块化形成。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-17 DOI: 10.1016/bs.acr.2024.06.011

Weiwei Wang, Hongjun Wang

{"title":"Modular formation of in vitro tumor models for oncological research/therapeutic drug screening.","authors":"Weiwei Wang, Hongjun Wang","doi":"10.1016/bs.acr.2024.06.011","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.06.011","url":null,"abstract":"In recognition of the lethal nature of cancer, extensive efforts have been made to understand the mechanistic causation while identifying the effective therapy modality in hope to eradicate cancerous cells with minimal damage to healthy cells. In search of such effective therapeutics, establishing pathophysiologically relevant in vitro models would be of importance in empowering our capabilities of truly identifying those potent ones with significantly reduction of the preclinical periods for rapid translation. In this regard, wealthy progresses have been achieved over past decades in establishing various in vitro and in vivo tumor models. Ideally, the tumor models should maximally recapture the key pathophysiological attributes of their native counterparts. Many of the current models have demonstrated their utilities but also showed some noticeable limitations. This book chapter will briefly review some of the mainstream platforms for in vitro tumor models followed by detailed elaboration on the modular strategies to form in vitro tumor models with complex structures and spatial organization of cellular components. Clearly, with the ability to modulate the building modules it becomes a new trend to form in vitro tumor models following a bottom-up approach, which offers a high flexibility to satisfy the needs for pathophysiological study, anticancer drug screening or design of personalized treatment.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"223-250"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic therapy landscape of advanced prostate cancer. 晚期前列腺癌的系统治疗前景。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-27 DOI: 10.1016/bs.acr.2024.04.004

Asit K Paul, John W Melson, Samina Hirani, Selvaraj Muthusamy

引用次数: 0

Melanoma redox biology and the emergence of drug resistance. 黑色素瘤氧化还原生物学和耐药性的出现。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-02 DOI: 10.1016/bs.acr.2024.06.004

Therese Featherston, Martina Paumann-Page, Mark B Hampton

引用次数: 0

Data enhancement in the age of spatial biology. 空间生物学时代的数据增强。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-09 DOI: 10.1016/bs.acr.2024.06.008

Linbu Liao, Patrick C N Martin, Hyobin Kim, Sanaz Panahandeh, Kyoung Jae Won

引用次数: 0

Recent advances and progress in immunotherapy of solid cancers. 实体癌免疫疗法的最新进展。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.acr.2024.05.004

Amit Kumar, Luni Emdad, Swadesh K Das, Paul B Fisher

{"title":"Recent advances and progress in immunotherapy of solid cancers.","authors":"Amit Kumar, Luni Emdad, Swadesh K Das, Paul B Fisher","doi":"10.1016/bs.acr.2024.05.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.05.004","url":null,"abstract":"Adoptive cell therapy using chimeric antigen receptor (CAR) technology has become mainstream by employing advanced engineering platforms to promote cancer immunotherapy. CAR T cells have shown remarkable efficacy in the treatment of hematological malignancies; however, the value of this therapy remains inconclusive in the context of solid tumors. Immunotherapy of solid tumors is restrained by several obstacles including the presence of an immunosuppressive tumor microenvironment (TME), limited tumor trafficking, inhibited immune cell infiltration, absence of tumor-specific antigens, and off-target toxicity and adverse events associated with these therapies. Despite recent advances in CAR T cell construction, including the integration of co-stimulatory domains and the creation of armed CAR T cells, with promising outcomes in the treatment of some solid tumors, there are still many unresolved obstacles that need to be overcome. To surmount these impediments to effective CAR T cell therapies, other immune cells, such as natural killer cells and macrophages, have been engineered to serve as appealing alternatives for successful cancer immunotherapy of solid tumors. CAR NK cells demonstrate significant clinical advantages due to their ready availability and minimal toxicity. CAR macrophage (M) cells provide considerable therapeutic potential due to their ability to penetrate the TME of solid tumors. In this review, we comprehensively examine the latest developments and prospects of engineered immune cell-based cancer immunotherapies specifically designed for treating solid tumors. In addition, we provide a concise overview of current clinical trials that are examining the safety and effectiveness of modified immune cells, such as CAR T, CAR NK, and CAR M, in their ability to specifically target solid tumors and promote improved therapeutic outcomes in patients with diverse solid cancers.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"111-190"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The glycosylation landscape of prostate cancer tissues and biofluids. 前列腺癌组织和生物流体的糖基化图谱

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-04-25 DOI: 10.1016/bs.acr.2024.04.005

Jordan Hartig, Lyndsay E A Young, Grace Grimsley, Anand S Mehta, Joseph E Ippolito, Robin J Leach, Peggi M Angel, Richard R Drake

{"title":"The glycosylation landscape of prostate cancer tissues and biofluids.","authors":"Jordan Hartig, Lyndsay E A Young, Grace Grimsley, Anand S Mehta, Joseph E Ippolito, Robin J Leach, Peggi M Angel, Richard R Drake","doi":"10.1016/bs.acr.2024.04.005","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.04.005","url":null,"abstract":"An overview of the role of glycosylation in prostate cancer (PCa) development and progression is presented, focusing on recent advancements in defining the N-glycome through glycomic profiling and glycoproteomic methodologies. Glycosylation is a common post-translational modification typified by oligosaccharides attached N-linked to asparagine or O-linked to serine or threonine on carrier proteins. These attached sugars have crucial roles in protein folding and cellular recognition processes, such that altered glycosylation is a hallmark of cancer pathogenesis and progression. In the past decade, advancements in N-glycan profiling workflows using Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI-MSI) technology have been applied to define the spatial distribution of glycans in PCa tissues. Multiple studies applying N-glycan MALDI-MSI to pathology-defined PCa tissues have identified significant alterations in N-glycan profiles associated with PCa progression. N-glycan compositions progressively increase in number, and structural complexity due to increased fucosylation and sialylation. Additionally, significant progress has been made in defining the glycan and glycopeptide compositions of prostatic-derived glycoproteins like prostate-specific antigen in tissues and biofluids. The glycosyltransferases involved in these changes are potential drug targets for PCa, and new approaches in this area are summarized. These advancements will be discussed in the context of the further development of clinical diagnostics and therapeutics targeting glycans and glycoproteins associated with PCa progression. Integration of large scale spatial glycomic data for PCa with other spatial-omic methodologies is now feasible at the tissue and single-cell levels.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"1-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Redox pathways in melanoma. 黑色素瘤的氧化还原途径

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-24 DOI: 10.1016/bs.acr.2024.06.002

Jie Zhang, Zhi-Wei Ye, Danyelle M Townsend, Kenneth D Tew

引用次数: 0

Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer. 前列腺癌治疗的进展：前列腺癌的放射性核素治疗。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-08-05 DOI: 10.1016/bs.acr.2024.07.004

Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata

{"title":"Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.","authors":"Jeffrey Zhong, Albert Jang, Jorge Garcia, Norbert Avril, Qiubai Li, Patrick Wojtylak, Neal Shore, Scott Tagawa, Pedro Barata","doi":"10.1016/bs.acr.2024.07.004","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.07.004","url":null,"abstract":"The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers concentrated doses of radiation via ionizing particles chelated to ligands or antibody-based molecules with specific tumor targets and is approved for patients with treatment resistant mCRPC. Variations of radionuclide therapies within the continuum of prostate cancer treatment are being investigated. Landmark phase III clinical trials of beta-emitting 177Lu-PSMA radionuclide therapy have demonstrated the utility of 177Lu-PSMA in the treatment of mCRPC. Further research into alpha-emitting radionuclide therapy and vectors may provide alternative treatments for patients with treatment resistant mCRPC. As radionuclide therapy treatment options evolve, assessing appropriate patient selection for radionuclide therapy is important and may be facilitated by advances in imaging and blood-based biomarkers. Exploration of other approved life prolonging therapies in combination with radionuclide therapy has shown increasing interest as a potential method of combatting radionuclide therapy resistance. In this chapter, we review various types of radionuclide therapies for mCRPC, patient selection for radionuclide therapy from outcome predictions, ongoing clinical trials of radiopharmaceuticals for treatment of prostate cancer, and the resistance mechanisms and challenges to radionuclide therapy.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"164 ","pages":"311-358"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0